UK markets close in 8 hours 28 minutes
  • FTSE 100

    6,651.96
    0.00 (0.00%)
     
  • FTSE 250

    21,198.12
    0.00 (0.00%)
     
  • AIM

    1,191.86
    0.00 (0.00%)
     
  • GBP/EUR

    1.1463
    -0.0034 (-0.30%)
     
  • GBP/USD

    1.3911
    -0.0102 (-0.73%)
     
  • BTC-GBP

    32,164.94
    -4,319.68 (-11.84%)
     
  • CMC Crypto 200

    891.58
    -41.55 (-4.45%)
     
  • S&P 500

    3,829.34
    -96.09 (-2.45%)
     
  • DOW

    31,402.01
    -559.85 (-1.75%)
     
  • CRUDE OIL

    62.76
    -0.77 (-1.21%)
     
  • GOLD FUTURES

    1,757.70
    -17.70 (-1.00%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    29,007.82
    -1,066.35 (-3.55%)
     
  • DAX

    13,879.33
    -96.67 (-0.69%)
     
  • CAC 40

    5,783.89
    -14.09 (-0.24%)
     

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Verona Pharma plc
·2-min read

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 7681320:

  • +1-888-317-6003 for callers in the United States

  • +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 90 days.

For further information, please contact:

Verona Pharma plc

US Tel: +1-833-417-0262
UK Tel: +44 (0)20 3283 4200

Victoria Stewart, Director of Communications

info@veronapharma.com

Argot Partners
(US Investor Enquiries)

Tel: +1 212-600-1902
verona@argotpartners.com

Kimberly Minarovich / Michael Barron

Optimum Strategic Communications
(International Media and European Investor Enquiries)

Tel: +44 (0)203 950 9144
verona@optimumcomms.com

Mary Clark / Eva Haas / Shabnam Bashir

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.